1 - Statement of Karen Midthun, M.D., Director, Office of
Vaccine Research and Review, CBER, FDA before the Committee
on Government Reform, United States House of Representatives,
December 10, 2002.
Reference 2 - Ball LK, Ball R, Pratt RD, An assessment of
thimerosal use in childhood vaccines, Pediatrics 2001; 1147-1154.
3 - Thimerosal in Vaccines. U.S. Food and Drug Administration,
Center for Biologics Evaluation and Research, Updated March
21, 2005. Available: http://www.fda.gov/cber/vaccine/thimerosal.htm
Reference 4 - Thimerosal-Containing Vaccines and Neurodevelopmental
Disorders, Institute of Medicine (IOM), Washington, D.C.: National
Academy Press; 2001. Published
Reference 5 - Immunization Safety Review: Vaccine and Autism,
Institute of Medicine (IOM), (Executive Summary, at 4) (emphasis
in original), Washington, D.C.: National Academy Press; 2004.
Reference 6 - Plotkin, Stanley A., et al, Vaccines, 4th Edition,
7 - Prevention and Control of Influenza: Recommendations
and Reports, CDC’s Advisory Committee on Immunization
Practices (ACIP), April 25, 2003. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5208a1.htm
Reference 8 Published